Cochlear earnings dive after litigation loss
As the coronavirus pandemic took hold and delayed elective surgeries, a patent infringement case judgment in the US was a major hit to hearing loss device developer Cochlear.
Cochlear
Rare chill for healthcare idols
Investors are faced with a difficult decision as two of the market’s favourite healthcare stocks suddenly catch cold.
Original URL: https://www.theaustralian.com.au/topics/cochlear/page/4